RxDoctor Payments Data

Brian Singeltary, DO

Hematology & Oncology · Cincinnati, OHNPI 1972890895

Payments from drug & device makers

$791in general payments, 2019–2025

Across 42 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$179
  • Pfizer$111
  • AstraZeneca$90
  • Gilead$64
  • GSK$42
  • Servier Pharmaceuticals LLC$40
  • plus $264 from 12 others

What the payments were for

  • Food & beverage$75495%
  • Education$375%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$791 in reported general payments places this provider in the 25th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$72,508
Medicare patients
238
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate43$587,754
ImbruvicaIbrutinib35$554,457
Lenalidomide22$324,197
KisqaliRibociclib Succinate16$270,131
InlytaAxitinib13$267,504
RevlimidLenalidomide14$257,199
IbrancePalbociclib15$237,278
BrukinsaZanubrutinib21$170,805
EliquisApixaban139$113,824
XareltoRivaroxaban52$64,921
Abiraterone Acetate17$55,047
Anastrozole292$4,286
Exemestane20$3,731
Letrozole118$2,042
Potassium Chloride56$1,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Ibrance, Eliquis$111$618,607167 claims
AstraZenecaCalquence$90$587,75443 claims
NovartisKisqali$179$270,13116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →